Cryptococcus neoformans as a Model for Radioimmunotherapy of Infections

There is an obvious and urgent need for novel approaches to treat infectious diseases. The use of monoclonal antibodies in therapy of infectious diseases is now experiencing renewed interest. During the last 5 years radioimmunotherapy (RIT), a modality previously developed only for cancer treatment...

Full description

Bibliographic Details
Main Authors: Ekaterina Dadachova, Arturo Casadevall
Format: Article
Language:English
Published: Hindawi Limited 2011-01-01
Series:Interdisciplinary Perspectives on Infectious Diseases
Online Access:http://dx.doi.org/10.1155/2011/830286
id doaj-743a297193ae41139cd80a590b640fe8
record_format Article
spelling doaj-743a297193ae41139cd80a590b640fe82020-11-24T22:16:24ZengHindawi LimitedInterdisciplinary Perspectives on Infectious Diseases1687-708X1687-70982011-01-01201110.1155/2011/830286830286Cryptococcus neoformans as a Model for Radioimmunotherapy of InfectionsEkaterina Dadachova0Arturo Casadevall1Department of Nuclear Medicine, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY 10461, USADepartment of Microbiology and Immunology, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY 10461, USAThere is an obvious and urgent need for novel approaches to treat infectious diseases. The use of monoclonal antibodies in therapy of infectious diseases is now experiencing renewed interest. During the last 5 years radioimmunotherapy (RIT), a modality previously developed only for cancer treatment, has been successfully adapted for the treatment of experimental fungal, bacterial, and viral infections. As our model organism for studying the efficacy, mechanisms, potential toxicity, and radioresistance to RIT, as well as for comparison of RIT with the existing antimicrobial therapies we have chosen the encapsulated yeast Cryptococcus neoformans (CN). The success of RIT approach in laboratory studies provides encouragement for feasibility of therapeutically targeting microbes with labeled antibodies. In addition, the creation of “panantibodies” for RIT which would recognize antigens shared by the whole class of pathogens such as fungi, for example, would facilitate the introduction of RIT into the clinic.http://dx.doi.org/10.1155/2011/830286
collection DOAJ
language English
format Article
sources DOAJ
author Ekaterina Dadachova
Arturo Casadevall
spellingShingle Ekaterina Dadachova
Arturo Casadevall
Cryptococcus neoformans as a Model for Radioimmunotherapy of Infections
Interdisciplinary Perspectives on Infectious Diseases
author_facet Ekaterina Dadachova
Arturo Casadevall
author_sort Ekaterina Dadachova
title Cryptococcus neoformans as a Model for Radioimmunotherapy of Infections
title_short Cryptococcus neoformans as a Model for Radioimmunotherapy of Infections
title_full Cryptococcus neoformans as a Model for Radioimmunotherapy of Infections
title_fullStr Cryptococcus neoformans as a Model for Radioimmunotherapy of Infections
title_full_unstemmed Cryptococcus neoformans as a Model for Radioimmunotherapy of Infections
title_sort cryptococcus neoformans as a model for radioimmunotherapy of infections
publisher Hindawi Limited
series Interdisciplinary Perspectives on Infectious Diseases
issn 1687-708X
1687-7098
publishDate 2011-01-01
description There is an obvious and urgent need for novel approaches to treat infectious diseases. The use of monoclonal antibodies in therapy of infectious diseases is now experiencing renewed interest. During the last 5 years radioimmunotherapy (RIT), a modality previously developed only for cancer treatment, has been successfully adapted for the treatment of experimental fungal, bacterial, and viral infections. As our model organism for studying the efficacy, mechanisms, potential toxicity, and radioresistance to RIT, as well as for comparison of RIT with the existing antimicrobial therapies we have chosen the encapsulated yeast Cryptococcus neoformans (CN). The success of RIT approach in laboratory studies provides encouragement for feasibility of therapeutically targeting microbes with labeled antibodies. In addition, the creation of “panantibodies” for RIT which would recognize antigens shared by the whole class of pathogens such as fungi, for example, would facilitate the introduction of RIT into the clinic.
url http://dx.doi.org/10.1155/2011/830286
work_keys_str_mv AT ekaterinadadachova cryptococcusneoformansasamodelforradioimmunotherapyofinfections
AT arturocasadevall cryptococcusneoformansasamodelforradioimmunotherapyofinfections
_version_ 1725790113798029312